why choose us

First received: October 25, 2023

Clinical Trial: Study of DF6215 in Patients With Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumor, Adult

Study Type: INTERVENTIONAL


Official Title: A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients With Advanced (Unresec

Brief Summary: DF6215-001 is a study of a modified human cytokine (interleukin-2; IL-2) that retains the ability to bind to a certain part of the IL-2 receptor on a subset of white blood cells (lymphocytes), which can help recognize and kill tumor cells.The study will occur in two phases.The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors.The second phase, Phase 1b, will include a dose expansion using the best dose selected from the first phase of the study.A cohort will be…

Read more